&lt;p&gt;Multidrug Resistance of Gastric Cancer: The Mechanisms and Chinese Medicine Reversal Agents&lt;/p&gt;

Huang, Wenjie; Ruan, Shuai; Fang, Wen; Lu, Xiaona; Gu, Suping; Chen, Xiaoxue; Liu, Miao; Shu, Ping

doi:10.2147/cmar.s274599

Cited by 33 publications

(23 citation statements)

References 40 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the continuous development of targeted therapy and immunotherapy in recent years has significantly improved the 5-year survival rate of patients with non-small cell lung cancer and the 5-year survival rate of patients with TPS ≥50% after immunotherapy could reach 31.9% ( Reck et al, 2019 ), high treatment costs and adverse reactions also deterred many patients from adhering to those therapies. Chinese patent medicine (CPM), as one of the development products under the theory of traditional Chinese medicine, is composed of natural ingredients and has been proved to be safe and effective ( Huang et al, 2020 ) in enhancing the efficacy of conventional treatments, alleviating adverse reactions ( Chen et al, 2014b ) and improving the patients’ quality of life ( Su et al, 2020 ). CPM is also more cost-effective to most people than western medicine and has been widely used in China.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Improvement in 2-Year Survival Rate of Patients with Stage II-III Non-Small Cell Lung Cancer Treated with Different Durations of Chinese Patent Medicine: A Retrospective Cohort Study

Wang

Ke²,

Li³

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Chinese patent medicine is widely used among patients with malignant tumors, and current studies have shown that long-term treatment with Chinese patent medicine is related to improved outcomes of patients. Huisheng Oral Liquid is a kind of Chinese patent medicine with the effects of curing dispersion-thirst and dissipating blood stasis. However, little is known about how it affects the survival rate of patients. Thus, patients with stage II-III NSCLC (non-small-cell lung cancer) were chosen to participate in a retrospective cohort study, which was conducted to preliminarily investigate the effects of using Chinese patent medicine and Huisheng Oral Liquid for different treatment durations on patients’ 2-year survival rate and explore the prognostic factors affecting the 2-year survival rate of those patients.Purpose: This work compares the effect of different durations of treatment with Chinese patent medicine and Huisheng Oral Liquid on the 2-year survival rate of patients with stage II-III NSCLC and explores the prognostic factors of the patients' 2-year survival rate.Methods: This retrospective cohort study included patients with non-small cell lung cancer stage II-III according to the 2015 NCCN Guidelines: Non-Small Cell Lung Cancer. The Kaplan–Meier method was used to compare the 2-year survival rate of patients treated with different durations of Chinese medicine and Huisheng Oral Liquid. The relationship between different treatment durations and degree of improvement of 2-year survival rate was explored using the Cochran–Armitage trend test. The Cox proportional-hazards regression models were used to explore factors affecting the 2-year survival rate of patients.Results: A total of 614 patients with stage II-III NSCLC diagnosed from January 2015 to December 2018 were included in this study. Patients treated with Chinese patent medicine were divided into three groups by treatment durations: < 3 months, ≥ 3 months, and ≥6 months, and those treated with Huisheng Oral Liquid were divided into < 3 months and ≥3 and ≥6 months. The results showed that ① the 2-year survival rate of patients treated with Chinese patent medicine for ≥3 months and ≥6 months was higher than that of patients treated for <3 months and the difference was statistically significant (p < 0.05). Further analysis of Huisheng Oral Liquid treatment revealed that ② the 2-year survival rate of patients treated with Huisheng Oral Liquid for ≥3 months was higher than that of patients treated for <3 months (p < 0.05). Because the total number of patients treated with Huisheng Oral Liquid for ≥6 months and the number of patients with improved outcomes were too small, there was no statistically significant difference in the 2-year survival rate between the two groups (p > 0.05). The results of the Cochran–Armitage trend test showed that the 2-year survival rate tended to increase with the duration of Huisheng Oral Liquid treatment (p < 0.05). ③ The Cox proportional -hazards regression model revealed that among all 614 patients, surgery [HR = 0.48, 95% CI = (0.34, 0.68)], chemotherapy [HR = 0.46, 95% CI = (0.31,0.67)], and treatment with Huisheng Oral Liquid for ≥3 months were protective factors [HR = 0.48, 95%CI = (0.27,0.88)], whereas male gender [HR = 1.59, 95% CI = (1.01, 2.50)] and FIB ≥4 g/L [HR = 1.95, 95% CI = (1.37, 2.77)] were risk factors.Conclusion: Chinese patent medicine treatment for ≥3 months showed an improvement in the 2-year survival rate of patients with stage II-III NSCLC. Patients treated with Huisheng Oral liquid for ≥3 months also showed an improvement in the 2-year survival rate, and the 2-year survival rate tended to increase as the treatment duration increased. Finally, male and FIB ≥ 4 g/L were risk factors for prognosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of Improvement in 2-Year Survival Rate of Patients with Stage II-III Non-Small Cell Lung Cancer Treated with Different Durations of Chinese Patent Medicine: A Retrospective Cohort Study

Wang

Ke²,

Li³

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Several studies have shown that surgery, radiotherapy and chemotherapy for GC are ineffective, while TCM treatment has its own advantages. It has great potential in improving immunity of body and alleviating symptoms caused by GC 46 . Although Piwei-Peiyuan Decoction has been widely used in treatment of GC, there is no research on its speci c mechanisms in treatment of GC.…”

Section: Discussionmentioning

confidence: 99%

Network Pharmacology-Based Approach to Investigate the Mechanisms of Piwei-Peiyuan Decoction in the Treatment of Gastric Carcinoma

Pei¹,

Wen²,

Zheng³

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose Piwei-Peiyuan Decoction is a traditional Chinese medicine decoction, which has shown promising treatment in gastric carcinoma. However, the molecular mechanisms of gastric carcinoma (GC) have not been systematically revealed yet. In this work, a network pharmacology research was conducted to analyze mechanisms of Piwei-Peiyuan Decoction, aiming to provide a basis for the development and application of new drugs in treatment of GC. Methods In this study, a network pharmacology approach was used to predict targets, construct network maps and analyze relevant signaling pathways. We discovered active chemical ingredients and their targets in the Piwei-Peiyuan Decoction by the TCMSP and ADME database. Then we found main targets of GC by GeneCards (https://www.genecards.org), OMIM (http://www.omim.org) and DRUGBANK (https://go.drugbank.com) databases. According to the information of ingredients and GC, a PPI network was performed by the String (https://string-db.org) database. And a targets-pathways interaction network was constructed by Cytoscape (version 3.7.2), a bioinformatics software used for data visualization and integration. Results Our result indicated that the main active ingredients of Piwei-Peiyuan Decoction in treating GC are Isorhamnetin, Kaempferol, Quercetin and Luteolin, and main active targets are CASP-3, MAPK1, MYC, AKT1, P53. We found the mechanism of Piwei-Peiyuan Decoction for treating GC is mainly to regulate PI3K-Akt signaling pathway, MAPK signaling pathway, Ras signaling pathway, IL-17 signaling pathway, HIF-1α signaling pathway to inhibit cell proliferation, promote apoptosis and then exert anti-cancer effects. Conclusion This study preliminarily analyzed the multi-component, multi-target and multi-path mechanism of Peiwei-Peiyuan Decoction in the treatment of gastric carcinoma, providing a theoretical basis for its clinical application.

show abstract

“…Chemotherapy is one of the important approaches to GC treatment. However, multidrug resistance (MDR) has become a common phenomenon, and it is a main reason for chemotherapy failure, making it difficult to improve the survival rate of patients with advanced GC (3). Therefore, overcoming the MDR of GC to chemotherapy and improving the efficacy of anticancer drugs are key issues in the global medical community.…”

Section: Introductionmentioning

confidence: 99%

Siteng Fang Reverses Multidrug Resistance in Gastric Cancer: A Network Pharmacology and Molecular Docking Study

2021

View full text Add to dashboard Cite

Siteng Fang (STF) has been shown to inhibit migration, invasion, and adhesion as well as promote apoptosis in gastric cancer (GC) cells. However, whether it can reverse the multidrug resistance (MDR) of GC to chemotherapy drugs is unknown. Thus, we aimed to elucidate the mechanism of STF in reversing the MDR of GC. The chemical composition of STF and genes related to GC were obtained from the TCMNPAS(TCM Network Pharmacology Analysis System, TCMNPAS) Database, and the targets of the active ingredients were predicted using the Swiss Target Prediction Database. The obtained data were mapped to obtain the key active ingredients and core targets of STF in treating GC. The active component-target network and protein interaction network were constructed by Cytoscape and String database, and the key genes and core active ingredients were obtained. The biological functions and related signal pathways corresponding to the key targets were analyzed and then verified via molecular docking. A total of 14 core active ingredients of STF were screened, as well as 20 corresponding targets, which were mainly enriched in cancer pathway, proteoglycan synthesis, PI3K-AKT signaling pathway, and focal adhesion. Molecular docking showed that the core active ingredients related to MDR, namely quercetin and diosgenin, could bind well to the target. In summary, STF may reverse the MDR of GC and exert synergistic effect with chemotherapeutic drugs. It mediates MDR mainly through the action of quercetin and diosgenin on the PI3K/AKT signaling pathway. These findings are the first to demonstrate the molecular mechanism of STF in reversing MDR in GC, thus providing a direction for follow-up basic research.

show abstract

<p>Multidrug Resistance of Gastric Cancer: The Mechanisms and Chinese Medicine Reversal Agents</p>

Cited by 33 publications

References 40 publications

Comparison of Improvement in 2-Year Survival Rate of Patients with Stage II-III Non-Small Cell Lung Cancer Treated with Different Durations of Chinese Patent Medicine: A Retrospective Cohort Study

Comparison of Improvement in 2-Year Survival Rate of Patients with Stage II-III Non-Small Cell Lung Cancer Treated with Different Durations of Chinese Patent Medicine: A Retrospective Cohort Study

Network Pharmacology-Based Approach to Investigate the Mechanisms of Piwei-Peiyuan Decoction in the Treatment of Gastric Carcinoma

Siteng Fang Reverses Multidrug Resistance in Gastric Cancer: A Network Pharmacology and Molecular Docking Study

Contact Info

Product

Resources

About